According to the latest report from The Times of India, a new study published in the "Hepatology" magazine in Germany found that flavonoids in green tea can inhibit the entry of hepatitis C virus (HVC) into the liver.
A new study by the Hannover Medical School in Germany found that green tea extract EGCG has an antiviral effect and can prevent hepatitis C infection after liver transplantation. According to World Health Organization statistics, hepatitis C virus infection can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) or deadly liver cancer. Hepatitis C virus is one of the common causes of chronic liver disease and one of the key indicators of liver transplantation. The world has 1.7 billion people infected with hepatitis C virus.
The researchers said that the current standard therapy for hepatitis C involves ribavirin and novel HVC protease inhibitors. These treatments can clearly identify hepatitis C in some patients, but they do not work in a large number of patients. In addition, re-infection of hepatic hepatitis C virus in healthy donors with liver transplants is also worthy of attention. The timely implementation of antiviral measures after liver transplantation to prevent reinfection of hepatitis C virus is an important measure to improve patient survival and quality of life.
Dr. Sandra Sisek and Dr. Eke Steinmann conducted in-depth studies on the role of EGCG molecules in preventing the attachment of hepatitis C virus to liver cells. Dr. Sisek said that green tea catechins such as EGCG and its derivatives, gallocatechin (EGC), epicatechin (ECG) and epicatechin (EC), all have antiviral and anticancer properties. The new study further explored the potential role of these flavonoids in preventing hepatitis C virus reinfection after liver transplantation. The results of the study showed that, unlike other derivatives of catechins, EGCG prevented the hepatitis C virus from entering the liver cells.
A new study by the Hannover Medical School in Germany found that green tea extract EGCG has an antiviral effect and can prevent hepatitis C infection after liver transplantation. According to World Health Organization statistics, hepatitis C virus infection can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) or deadly liver cancer. Hepatitis C virus is one of the common causes of chronic liver disease and one of the key indicators of liver transplantation. The world has 1.7 billion people infected with hepatitis C virus.
The researchers said that the current standard therapy for hepatitis C involves ribavirin and novel HVC protease inhibitors. These treatments can clearly identify hepatitis C in some patients, but they do not work in a large number of patients. In addition, re-infection of hepatic hepatitis C virus in healthy donors with liver transplants is also worthy of attention. The timely implementation of antiviral measures after liver transplantation to prevent reinfection of hepatitis C virus is an important measure to improve patient survival and quality of life.
Dr. Sandra Sisek and Dr. Eke Steinmann conducted in-depth studies on the role of EGCG molecules in preventing the attachment of hepatitis C virus to liver cells. Dr. Sisek said that green tea catechins such as EGCG and its derivatives, gallocatechin (EGC), epicatechin (ECG) and epicatechin (EC), all have antiviral and anticancer properties. The new study further explored the potential role of these flavonoids in preventing hepatitis C virus reinfection after liver transplantation. The results of the study showed that, unlike other derivatives of catechins, EGCG prevented the hepatitis C virus from entering the liver cells.
China High Speed Centrifuge,Ultra High Speed Centrifuge manufacturer, choose the high quality High Speed Refrigerated Centrifuge,High Speed Centrifuge Rpm, etc.
High Speed Centrifuge,Ultra High Speed Centrifuge,High Speed Refrigerated Centrifuge,High Speed Centrifuge Rpm
Zenith Lab (Jiangsu) Co.,Ltd , https://www.zenithlabo.com